Contact this trialFirst, we need to learn more about you.
Immunomodulator
Venetoclax + Lenalidomide + Rituximab for Non-Hodgkin's Lymphoma
Recruiting1 awardPhase 1
Philadelphia, Pennsylvania
This trial is testing the combination of venetoclax, lenalidomide, and rituximab hyaluronidase to treat patients with relapsed or refractory low-grade lymphoma. The goal is to find the maximum tolerated dose of venetoclax and to learn about the side effects of this combination.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service